Barinthus Biotherapeutics (BRNS) Change in Accured Expenses (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has 7 years of Change in Accured Expenses data on file, last reported at $2.6 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 202.54% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 205.79% YoY) and the FY2025 annual result came in at -$3.8 million, down 931.8% from the prior year.
• Change in Accured Expenses grew to $2.6 million in Q1 2026, from -$453000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.6 million in Q3 2022 to a low of -$4.3 million in Q4 2022.
• A 5-year average of $117235.3 and a median of -$453000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 2720.37% in 2022, down 479.63% in 2022.
• Tracing BRNS's Change in Accured Expenses over 5 years: stood at -$4.3 million in 2022, then advanced by 24.89% to -$3.2 million in 2023, then surged by 161.22% to $2.0 million in 2024, then sank by 122.83% to -$453000.0 in 2025, then surged by 670.86% to $2.6 million in 2026.
• The last three Change in Accured Expenses figures came in at $2.6 million (Q1 2026), -$453000.0 (Q4 2025), and -$573000.0 (Q3 2025), per Business Quant data.